Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Resveratrol + quercetin + curcumin is a combination of three natural polyphenolic compounds—resveratrol, quercetin, and curcumin—each derived from medicinal plants and widely studied for their antioxidant, anti-inflammatory, and anticancer properties. This combination has been investigated as a dietary supplement and experimental antitumor compound (sometimes referred to as "RCQ") for its potential synergistic effects in cancer therapy, bone metabolism disorders (such as osteoporosis), periodontitis, neurodegenerative diseases, cardiovascular disease, diabetes, aging-related conditions, and inflammation. Mechanistically, the combination acts through multiple pathways including inhibition of cyclooxygenase (COX) enzymes and inducible nitric oxide synthase (iNOS), suppression of the NF-κB pathway leading to reduced proinflammatory cytokine production and immune cell proliferation/migration in the tumor microenvironment. The combined use enhances bioavailability compared to single agents alone[1][3][4][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on resveratrol + quercetin + curcumin.